Cocrystal Pharma Inc
cocrystalpharma.comWhat Do They Do?
Develops small-molecule antiviral drug candidates for human viral diseases, including influenza, norovirus, coronaviruses and hepatitis C.
10-K for FY2025, filed Mar 31, 2026
How Are They Changing?
-
Sep 9, 2026
The last subject was dosed in the norovirus challenge study
Preliminary efficacy results are expected in late 2026 or early 2027.
Sources
8-K, filed Sep 9, 2026
Preliminary efficacy results expected in late 2026 or early 2027View ↗
-
Aug 3, 2026
OPKO Health invested $5.0 million in a private placement
Cocrystal sold OPKO Health common shares to fund drug programs and working capital.
Sources
8-K, filed Aug 3, 2026
On July 31, 2026, Cocrystal Pharma, Inc. (the “Company” or “Cocrystal”) entered into a Securities Purchase Agreement (“SPA”) with OPKO…View ↗
-
Jun 9, 2026
James Sapirstein was appointed chief executive officer
Sources
8-K, filed Jun 9, 2026
On June 3, 2026, the Board of Directors (the “Board”) of Cocrystal Pharma, Inc. (the “Company”) appointed James Sapirstein as the Chief…View ↗
Broader target viruses
The latest report describes development across influenza, norovirus, coronaviruses and hepatitis C, while the older report also emphasized working through partnerships or licensing to advance its hepatitis C candidate.
10-K for FY2022, filed Mar 29, 2023 10-K for FY2025, filed Mar 31, 2026We are developing antiviral therapeutics that inhibit the essential viral replication function of RNA viruses causing acute and chronic…View ↗
Who Do They Compete With?
Competes with Roche, Gilead Sciences, Merck, Janssen Pharmaceuticals, Bristol-Myers Squibb, Toyama Chemical, Shionogi/Roche, Abbvie, Pfizer, and Moderna
10-K for FY2025, filed Mar 31, 2026The biotechnology and pharmaceutical industries are subject to intense and rapidly changing competition as companies seek to develop new…View ↗
Loading...
